throbber

`
`
`• Women with history of unexplained vaginal bleeding (4.4)
`
`
`• Women with endometrial hyperplasia with atypia or
`
`endometrial carcinoma (4.4)
`-----------------WARNINGS AND PRECAUTIONS--------------
`
`• Adrenal insufficiency: Patients should be closely monitored
`
`for signs and symptoms of adrenal insufficiency (5.1).
`
`
`• Hypokalemia: Hypokalemia should be corrected prior to
`
`treatment and monitored for during treatment (5.2).
`
`
`• Vaginal bleeding and endometrial changes: Women may
`
`
`experience endometrial thickening or unexpected vaginal
`bleeding. Use with caution if patient also has a hemorrhagic
`
`disorder or is on anti-coagulant therapy (5.3).
`
`• QT interval prolongation: Avoid use with QT interval-
`prolonging drugs, or in patients with potassium channel
`
`variants resulting in a long QT interval (5.4).
`
`
`• Use of Strong CYP3A Inhibitors: Concomitant use can
`increase mifepristone plasma levels significantly. Use only
`
`when necessary and limit mifepristone dose to 300 mg (5.6).
`
`
`
`
`
`
`
`
`----------------------ADVERSE REACTIONS-----------------------
`Most common adverse reactions in Cushing’s syndrome
`(≥ 20%): nausea, fatigue, headache, decreased blood potassium,
`
`arthralgia, vomiting, peripheral edema, hypertension, dizziness,
`
`decreased appetite, endometrial hypertrophy
`
`
`To report suspected adverse reactions, contact Corcept
`Therapeutics at 1-855-844-3270 or FDA at 1-800-FDA-
`1088 or www.fda.gov/medwatch.
`
`----------------------DRUG INTERACTIONS---------------------
`• Drugs metabolized by CYP3A: Administer drugs that are
`metabolized by CYP3A at the lowest dose when used with
`Korlym (7.1).
`• CYP3A inhibitors: Caution should be used when Korlym is
`
`used with strong CYP3A inhibitors. Limit mifepristone dose to
`
`300 mg per day when used with strong CYP3A inhibitors (5.6,
`
`
`7.2).
`
`• CYP3A inducers: Do not use Korlym with CYP3A inducers
`
`(7.3).
`• Drugs metabolized by CYP2C8/2C9: Use the lowest dose of
`CYP2C8/2C9 substrates when used with Korlym (7.4).
`
`• Drugs metabolized by CYP2B6: Use of Korlym should be
`done with caution with bupropion and efavirenz (7.5).
`
`• Hormonal contraceptives: Do not use with Korlym (7.6).
`
`
`-----------------USE IN SPECIFIC POPULATIONS--------------
`
`• Nursing mothers: Discontinue drug or discontinue nursing
`
`(8.3).
`
`
`See Section 17 for PATIENT COUNSELING
`INFORMATION and FDA-approved Medication Guide
`
`
`
`HIGHLIGHTS OF PRESCRIBING INFORMATION
`These highlights do not include all the information
`needed to use Korlym™ safely and effectively. See full
`
`prescribing information for Korlym.
`
`Korlym™ (mifepristone) 300 mg Tablets
`Initial U.S Approval 2000
`
`
`WARNING: TERMINATION OF PREGNANCY
`
`See full prescribing information for complete boxed warning.
`Mifepristone has potent antiprogestational effects and will
`result in the termination of pregnancy. Pregnancy must
`therefore be excluded before the initiation of treatment with
`Korlym, or if treatment is interrupted for more than 14 days
`in females of reproductive potential.
`
`
`
`--------------------INDICATIONS AND USAGE-------------------
`Korlym (mifepristone) is a cortisol receptor blocker indicated to
`control hyperglycemia secondary to hypercortisolism in adult
`
`patients with endogenous Cushing's syndrome who have type 2
`diabetes mellitus or glucose intolerance and have failed surgery
`or are not candidates for surgery.
`
`
`Important Limitations of Use (1.1)
`
`Do not use for the treatment of type 2 diabetes
`
`mellitus unrelated to endogenous Cushing’s
`syndrome.
`
`
`
`
`
`----------------DOSAGE AND ADMINISTRATION--------------
`
`Administer once daily orally with a meal (2).
`
`
`The recommended starting dose is 300 mg once daily
`
`(2).
`
`Renal impairment: do not exceed 600 mg once daily.
`
`
` Mild-to-moderate hepatic impairment: do not exceed
`600 mg once daily. Do not use in severe hepatic
`impairment.
`
`
`
`Based on clinical response and tolerability, the dose may be
`increased in 300 mg increments to a maximum of 1200 mg once
`daily. Do not exceed 20 mg/kg per day (2).
`
`---------------DOSAGE FORMS AND STRENGTHS------------
`
`• 300 mg tablet
`
`------------------------CONTRAINDICATIONS---------------------
`
`• Pregnancy (4.1, 8.1)
`
`
`• Use of simvastatin or lovastatin and CYP 3A substrates with
`narrow therapeutic range (4.2)
`
`• Concurrent long-term corticosteroid use (4.3)
`
`
`
`
`
`
`
`
`Reference ID: 3089791
`
`1
`
`
`

`

`FULL PRESCRIBING INFORMATION: Contents*

`1 INDICATIONS AND USAGE

`LIMITATIONS OF USE:

`2 DOSAGE AND ADMINISTRATION

`2.1 Adult Dosage
`

`2.2 Dosing in Renal Impairment
`

`2.3 Dosing in Hepatic Impairment
`

`3 DOSAGE FORMS AND STRENGTHS

`4 CONTRAINDICATIONS

`4.1 Pregnancy
`

`4.2 Drugs Metabolized by CYP3A
`

`4.3 Corticosteroid Therapy Required for
`
`Lifesaving Purposes
`

`4.4 Women with Risk of Vaginal Bleeding or
`
`Endometrial Changes
`

`4.5 Known Hypersensitivity to Mifepristone
`

`5 WARNINGS AND PRECAUTIONS

`5.1 Adrenal Insufficiency
`

`5.2 Hypokalemia
`

`5.3 Vaginal Bleeding and Endometrial
`
`Changes
`

`5.4 QT Interval Prolongation
`

`5.5 Exacerbation/Deterioration of Conditions
`
`Treated with Corticosteroids
`

`5.6 Use of Strong CYP3A Inhibitors
`

`5.7 Pneumocystis jiroveci Infection
`

`5.8 Potential Effects of Hypercortisolemia
`

`6 ADVERSE REACTIONS

`6.1 Clinical Trials Experience
`

`6.2 Laboratory Tests
`

`6.3 Vaginal Bleeding and Endometrial
`
`Changes
`

`6.4 Additional Data from Clinical Trials
`
`

`
`6.4.1 Adrenal Insufficiency
`

`6.4.2 Rash
`

`7 DRUG INTERACTIONS

`7.1 Drugs Metabolized by CYP3A
`

`7.2 CYP3A Inhibitors
`

`7.3 CYP3A Inducers
`

`7.4 Drugs Metabolized by CYP2C8/2C9
`

`7.5 Drugs Metabolized by CYP2B6
`

`7.6 Use of Hormonal Contraceptives
`

`8 USE IN SPECIFIC POPULATIONS

`8.1 Pregnancy
`

`8.3 Nursing Mothers
`
`

`8.4 Pediatric Use
`

`8.5 Geriatric Use
`

`8.6 Renal Impairment
`

`8.7 Hepatic Impairment
`

`8.8 Females of Reproductive Potential
`

`10 OVERDOSAGE

`11 DESCRIPTION

`12 CLINICAL PHARMACOLOGY

`12.1 Mechanism of Action
`

`12.2 Pharmacodynamics
`

`12.3 Pharmacokinetics
`

`13 NONCLINICAL TOXICOLOGY

`13.1 Carcinogenesis, Mutagenesis,
`
`Impairment of Fertility
`

`14 CLINICAL STUDIES

`14.1 Cushing’s Syndrome
`

`16 HOW SUPPLIED/STORAGE AND
`HANDLING

`17 PATIENT COUNSELING
`INFORMATION

`17.1 Importance of Preventing Pregnancy
`

`
`
`*Sections or subsections omitted from the full prescribing information are not listed
`
`
`Reference ID: 3089791
`
`2
`
`
`

`

`
`Korlym™ (mifepristone) 300 mg tablets for oral use
`
`
`FULL PRESCRIBING INFORMATION
`
`
`
`WARNING: TERMINATION OF PREGNANCY
`Mifepristone is a potent antagonist of progesterone and cortisol via the progesterone and
`glucocorticoid (GR-II) receptors, respectively. The antiprogestational effects will result in the
`termination of pregnancy. Pregnancy must therefore be excluded before the initiation of treatment
`with Korlym and prevented during treatment and for one month after stopping treatment by the
`use of a non-hormonal medically acceptable method of contraception unless the patient has had a
`surgical sterilization, in which case no additional contraception is needed. Pregnancy must also be
`excluded if treatment is interrupted for more than 14 days in females of reproductive potential.
`
`
`1 INDICATIONS AND USAGE
`Korlym (mifepristone) is a cortisol receptor blocker indicated to control hyperglycemia secondary to
`hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes
`
`mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
`
`LIMITATIONS OF USE:
`
` Korlym should not be used in the treatment of patients with type 2 diabetes unless it is secondary
`to Cushing’s syndrome.
`
`
`
`2 DOSAGE AND ADMINISTRATION
`
`2.1 Adult Dosage
`The recommended starting dose is 300 mg orally once daily. Korlym must be given as a single daily dose.
`
`
`Korlym should always be taken with a meal. Patients should swallow the tablet whole. Do not split, crush,
`or chew tablets.
`
`Dosing and titration
`
`The daily dose of Korlym may be increased in 300 mg increments. The dose of Korlym may be increased
`
`
`to a maximum of 1200 mg once daily but should not exceed 20 mg/kg per day. Increases in dose should
`
`not occur more frequently than once every 2-4 weeks. Decisions about dose increases should be based on
`
`a clinical assessment of tolerability and degree of improvement in Cushing’s syndrome manifestations.
`Changes in glucose control, anti-diabetic medication requirements, insulin levels, and psychiatric
`symptoms may provide an early assessment of response (within 6 weeks) and may help guide early dose
`titration. Improvements in cushingoid appearance, acne, hirsutism, striae, and body weight occur over a
`longer period of time and, along with measures of glucose control, may be used to determine dose
`changes beyond the first 2 months of therapy. Careful and gradual titration of Korlym accompanied by
`
`monitoring for recognized adverse reactions (See Warnings and Precautions 5.1 and 5.2) may reduce the
`
`
`risk of severe adverse reactions. Dose reduction or even dose discontinuation may be needed in some
`
`
`Reference ID: 3089791
`
`3
`
`
`

`

`clinical situations. If Korlym treatment is interrupted, it should be reinitiated at the lowest dose (300 mg).
`If treatment was interrupted because of adverse reactions, the titration should aim for a dose lower than
`the one that resulted in treatment interruption.
`
`2.2 Dosing in Renal Impairment
`No change in initial dose of Korlym is required in renal impairment. The maximum dose should be
`limited to 600 mg. [See Renal Impairment (8.6) and Clinical Pharmacology (12.3)]
`
`
`2.3 Dosing in Hepatic Impairment
`No change in the initial dose of Korlym is required in mild to moderate hepatic impairment. The
`maximum dose should be limited to 600 mg. Korlym should not be used in severe hepatic impairment.
`
`[See Hepatic Impairment (8.7) and Clinical Pharmacology (12.3)]
`
`
`3 DOSAGE FORMS AND STRENGTHS
`Korlym is supplied as a light yellow to yellow oval-shaped tablet debossed with “Corcept” on one side
`and “300” on the other. Each tablet contains 300 mg of mifepristone. The tablets are not scored.
`
`
`4 CONTRAINDICATIONS
`
`4.1 Pregnancy
`Korlym is contraindicated in women who are pregnant. Pregnancy must be excluded before the initiation
`
`of treatment with Korlym or if treatment is interrupted for more than 14 days in females of reproductive
`
`
`potential. Nonhormonal contraceptives should be used during and one month after stopping treatment in
`all women of reproductive potential. [See Use in Specific Populations 8.8]
`
`
`4.2 Drugs Metabolized by CYP3A
`Korlym is contraindicated in patients taking simvastatin, lovastatin, and CYP3A substrates with narrow
`therapeutic ranges, such as cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide,
`quinidine, sirolimus, and tacrolimus, due to an increased risk of adverse events. [See Drug Interactions
`(7.1) and Clinical Pharmacology (12.3)]
`
`
`4.3 Corticosteroid Therapy Required for Lifesaving Purposes
`Korlym is contraindicated in patients who require concomitant treatment with systemic corticosteroids for
`serious medical conditions or illnesses (e.g., immunosuppression after organ transplantation) because
`Korlym antagonizes the effect of glucocorticoids.
`
`4.4 Women with Risk of Vaginal Bleeding or Endometrial Changes
`Korlym is contraindicated in the following:
`
` Women with a history of unexplained vaginal bleeding
`
` Women with endometrial hyperplasia with atypia or endometrial carcinoma
`
`4.5 Known Hypersensitivity to Mifepristone
`
`Korlym is contraindicated in patients with prior hypersensitivity reactions to mifepristone or to any of the
`product components.
`
`Reference ID: 3089791
`
`4
`
`
`

`

`5 WARNINGS AND PRECAUTIONS
`
`5.1 Adrenal Insufficiency
`Patients receiving mifepristone may experience adrenal insufficiency. Because serum cortisol levels
`remain elevated and may even increase during treatment with Korlym, serum cortisol levels do not
`provide an accurate assessment of hypoadrenalism in patients receiving Korlym. Patients should be
`
`closely monitored for signs and symptoms of adrenal insufficiency, including weakness, nausea,
`increased fatigue, hypotension, and hypoglycemia. If adrenal insufficiency is suspected, discontinue
`treatment with Korlym immediately and administer glucocorticoids without delay. High doses of
`supplemental glucocorticoids may be needed to overcome the glucocorticoid receptor blockade produced
`by mifepristone. Factors considered in deciding on the duration of glucocorticoid treatment should
`
`include the long half-life of mifepristone (85 hours).
`
`Treatment with Korlym at a lower dose can be resumed after resolution of adrenal insufficiency. Patients
`should also be evaluated for precipitating causes of hypoadrenalism (infection, trauma, etc.).
`
`
`5.2 Hypokalemia
`In a study of patients with Cushing’s syndrome, hypokalemia was observed in 44% of subjects during
`
`treatment with Korlym. Hypokalemia should be corrected prior to initiating Korlym. During Korlym
`
`administration, serum potassium should be measured 1 to 2 weeks after starting or increasing the dose of
`Korlym and periodically thereafter. Hypokalemia can occur at any time during Korlym treatment.
`Mifepristone-induced hypokalemia should be treated with intravenous or oral potassium supplementation
`based on event severity. If hypokalemia persists in spite of potassium supplementation, consider adding
`mineralocorticoid antagonists.
`
`5.3 Vaginal Bleeding and Endometrial Changes
`Being an antagonist of the progesterone receptor, mifepristone promotes unopposed endometrial
`proliferation that may result in endometrium thickening, cystic dilatation of endometrial glands, and
`vaginal bleeding. Korlym should be used with caution in women who have hemorrhagic disorders or are
`receiving concurrent anticoagulant therapy. Women who experience vaginal bleeding during Korlym
`
`treatment should be referred to a gynecologist for further evaluation.
`
`5.4 QT Interval Prolongation
`Mifepristone and its metabolites block IKr. Korlym prolongs the QTc interval in a dose-related manner.
`
`There is little or no experience with high exposure, concomitant dosing with other QT-prolonging
`drugs, or potassium channel variants resulting in a long QT interval. [See Warnings & Precautions
`(5.6)] To minimize risk, the lowest effective dose should always be used.
`
`
`5.5 Exacerbation/Deterioration of Conditions Treated with Corticosteroids
`Use of Korlym in patients who receive corticosteroids for other conditions (e.g., autoimmune disorders)
`may lead to exacerbation or deterioration of such conditions, as Korlym antagonizes the desired effects of
`glucocorticoid in these clinical settings. For medical conditions in which chronic corticosteroid therapy is
`life-saving (e.g., immunosuppression in organ transplantation), Korlym is contraindicated. [See
`
`Contraindications (4.3)]
`
`
`Reference ID: 3089791
`
`5
`
`
`

`

`5.6 Use of Strong CYP3A Inhibitors
`Korlym should be used with extreme caution in patients taking ketoconazole and other strong inhibitors
`of CYP3A, such as itraconazole, nefazodone, ritonavir, nelfinavir, indinavir, atazanavir, amprenavir,
`fosamprenavir, boceprevir, clarithromycin, conivaptan, lopinavir, nefazodone, posaconazole, ritonavir,
`saquinavir, telaprevir, telithromycin, or voriconazole, as these could substantially increase the
`concentration of mifepristone in the blood. The benefit of concomitant use of these agents should be
`carefully weighed against the potential risks. Mifepristone should be used in combination with strong
`CYP3A inhibitors only when necessary, and in such cases the dose should be limited to 300 mg per day.
`
`
`[See Warnings & Precautions (5.4), Drug Interactions (7.2), and Clinical Pharmacology (12.3)]
`
`
`5.7 Pneumocystis jiroveci Infection
`
`Patients with endogenous Cushing’s syndrome are at risk for opportunistic infections such as
`Pneumocystis jiroveci pneumonia during Korlym treatment. Patients may present with respiratory distress
`shortly after initiation of Korlym. Appropriate diagnostic tests should be undertaken and treatment for
`Pneumocystis jiroveci should be considered.
`
`5.8 Potential Effects of Hypercortisolemia
`Korlym does not reduce serum cortisol levels. Elevated cortisol levels may activate mineralcorticoid
`
`receptors which are also expressed in cardiac tissues. Caution should be used in patients with underlying
`heart conditions including heart failure and coronary vascular disease.
`
`6 ADVERSE REACTIONS
`
`6.1 Clinical Trials Experience
`Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed
`
`cannot be directly compared to rates in other clinical trials and may not reflect the rates observed in
`clinical practice.
`
`Safety data on the use of Korlym are available from 50 patients with Cushing’s syndrome enrolled in an
`
`uncontrolled, open-label, multi-center trial (Study 400). Forty-three patients had Cushing’s disease and all
`except one had previously undergone pituitary surgery. Four patients had ectopic ACTH secretion, and
`
`three had adrenal carcinoma. Patients were treated for up to 24 weeks. A dose of 300 mg per day was
`administered for the initial 14 days; thereafter, the dose could be escalated in increments of 300 mg per
`day based on assessments of tolerability and clinical response. Doses were escalated up to 900 mg per day
`
`
`for patients <60 kg, or 1200 mg per day for patients >60 kg.
`
`
`The most frequently reported adverse reactions (reported in ≥20% of patients, regardless of relationship to
`Korlym) were nausea, fatigue, headache, decreased blood potassium, arthralgia, vomiting, peripheral
`edema, hypertension, dizziness, decreased appetite, and endometrial hypertrophy. Drug-related adverse
`events resulted in dose interruption or reduction in study drug in 40% of patients.
`
`The adverse reactions that occurred in ≥10% of the Cushing’s syndrome patients receiving Korlym,
`regardless of relationship to Korlym, are shown in Table 1.
`
`Reference ID: 3089791
`
`6
`
`
`

`

`Table 1. Treatment Emergent Adverse Events Occurring in ≥10% of Cushing’s Syndrome Patients
`Receiving Korlym
`
`
`
`Body System/Adverse Reaction
`
`Percent (%) of
`Patients Reporting
`Event
`(n = 50)
`
`Gastrointestinal disorders
`
`Nausea
`Vomiting
`Dry mouth
`Diarrhea
`Constipation
`General disorders and administration/site conditions
`
`Fatigue
`Edema peripheral
`Pain
`Nervous system disorders
`
`Headache
`Dizziness
`Somnolence
`Musculoskeletal and connective tissue disorders
`
`Arthralgia
`Back pain
`Myalgia
`
`Pain in extremity
`Investigations
`
`
`Blood potassium decreased
`Thyroid function test abnormal
`Infections and infestations
`
`Sinusitis
`Nasopharyngitis
`Metabolism and nutrition disorders
`
`Decreased appetite
`Anorexia
`Vascular disorders
`
`Hypertension
`
`Reproductive system and breast disorders
`
`Endometrial hypertrophy
`
`Respiratory, thoracic, and mediastinal disorders
`
`Dyspnea
`Psychiatric disorders
`
`10
`Anxiety
`
`*The denominator was 26 females who had baseline and end-of-trial transvaginal ultrasound
`
`
`48
`26
`18
`12
`10
`
`48
`26
`14
`
`44
`22
`10
`
`30
`16
`14
`12
`
`34
`18
`
`14
`12
`
`20
`10
`
`24
`
`38*
`
`16
`
`Reference ID: 3089791
`
`
`7
`
`
`

`

`6.2 Laboratory Tests
`
`Reductions in high density lipoprotein-cholesterol (HDL-C) levels have been observed following
`treatment with Korlym. In study subjects that experienced declines in HDL-C, levels returned to baseline
`following discontinuation of drug. The clinical significance of the treatment-related reduction in HDL-C
`levels in patients with Cushing’s syndrome is not known.
`
`
`In a study of patients with Cushing’s syndrome, hypokalemia was observed in 44% of subjects during
`
`treatment with Korlym. In these cases, hypokalemia responded to treatment with potassium
`supplementation and/or mineralocorticoid antagonist therapy (e.g., spironolactone or eplerenone).
`
`Hypokalemia should be corrected prior to initiating Korlym. [See Warnings and Precautions (5.2)]
`
`
`
`Elevations of thyroid-stimulating hormone (TSH) were seen in subjects treated with Korlym. Of the
`42 subjects with detectable TSH at baseline, eight (19%) had increases in TSH above the normal range,
`while remaining asymptomatic. The TSH levels returned to normal in most patients without intervention
`when Korlym was discontinued at the end of the study.
`
`6.3 Vaginal Bleeding and Endometrial Changes
`In Study 400, the thickness of the endometrium increased from a mean of 6.14 mm at baseline (n=23) to
`
`15.7 mm at end-of-trial (n=18) in premenopausal women; in postmenopausal women the increase was
`from 2.75 mm (n=6) to 7.35 mm (n=8). Endometrial thickness above the upper limit of normal was
`reported in 10/26 females who had baseline and end-of-trial transvaginal ultrasound (38%). The
`endometrial thickness returned to the normal range in 3 out of 10 patients 6 weeks after treatment
`cessation at the end of the study. Vaginal bleeding occurred in 5 out of 35 females (14%). Two of five
`subjects with vaginal bleeding had normal endometrial thickness. Endometrial biopsies were performed in
`six patients; five of these patients had endometrial thickening. No endometrial carcinoma was detected in
`the sampled cases.
`
`
`6.4 Additional Data from Clinical Trials
`The following are adverse events that were reported in Study 400 at frequencies of ≥ 5% to 10%, and may
`
`be related to Korlym’s mechanism of action:
`
`Gastrointestinal disorders: gastroesophageal reflux, abdominal pain
`General disorders and administration site conditions: asthenia, malaise, edema, pitting edema, thirst
`Investigations: blood triglycerides increased
`Metabolism and nutrition disorders: hypoglycemia
`Musculoskeletal and connective tissue disorders: muscular weakness, flank pain, musculoskeletal chest
`
`pain
`Psychiatric disorders: insomnia
`
`Reproductive system and breast disorders: vaginal hemorrhage, metrorrhagia [See Warnings and
`
`Precautions (5.3)]
`
`
`6.4.1 Adrenal Insufficiency
`Adrenal insufficiency was reported in two subjects (4%) in Study 400. The most typical symptoms of
`adrenal insufficiency were nausea and decreased appetite. No hypotension or hypoglycemia was reported
`
`Reference ID: 3089791
`
`8
`
`
`

`

`during the events. Adrenal insufficiency resolved in both cases with Korlym interruption and /or
`
`dexamethasone administration.
`
`6.4.2 Rash
`Generalized, maculo-papular rash was reported in 2 subjects (4%) in Study 400. Two additional subjects
`developed pruritus (4%). None resulted in discontinuation of Korlym, and all the events resolved by the
`end of the study.
`
`7 DRUG INTERACTIONS
`Based on the long terminal half-life of mifepristone after reaching steady state, at least 2 weeks should
`elapse after cessation of Korlym before initiating or increasing the dose of any interacting concomitant
`medication.
`
`7.1 Drugs Metabolized by CYP3A
`Because Korlym is an inhibitor of CYP3A, concurrent use of Korlym with a drug whose metabolism is
`largely or solely mediated by CYP3A is likely to result in increased plasma concentrations of the drug.
`
`Discontinuation or dose reduction of such medications may be necessary with Korlym co-administration.
`
`Korlym increased the exposure to simvastatin and simvastatin acid significantly in healthy subjects.
`Concomitant use of simvastatin or lovastatin is contraindicated because of the increased risk of myopathy
`
`and rhabdomyolysis. [See Contraindications (4.2), Clinical Pharmacology 12.3]
`
`
`The exposure of other substrates of CYP3A with narrow therapeutic ranges, such as cyclosporine,
`dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus, may be
`
`increased by concomitant administration with Korlym. Therefore, the concomitant use of such CYP3A
`
`substrates with Korlym is contraindicated. [See Contraindications (4.2)]
`
`
`Other drugs with similar high first pass metabolism in which CYP3A is the primary route of metabolism
`
`should be used with extreme caution if co-administered with Korlym. The lowest possible dose and/or a
`decreased frequency of dosing must be used with therapeutic drug monitoring when possible. Use of
`alternative drugs without these metabolic characteristics is advised when possible with concomitant
`Korlym.
`
`If drugs that undergo low first pass metabolism by CYP3A or drugs in which CYP3A is not the major
`metabolic route are co-administered with Korlym, use the lowest dose of concomitant medication
`necessary, with appropriate monitoring and follow-up. [See Clinical Pharmacology (12.3)]
`
`
`7.2 CYP3A Inhibitors
`Medications that inhibit CYP3A could increase plasma mifepristone concentrations and dose reduction of
`Korlym may be required.
`
`
`Ketoconazole and other strong inhibitors of CYP3A, such as itraconazole, nefazodone, ritonavir,
`nelfinavir, indinavir, atazanavir, amprenavir and fosamprenavir, boceprevir, clarithromycin, conivaptan,
`lopinavir, mibefradil, nefazodone, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, or
`voriconazole may increase exposure to mifepristone significantly. The clinical impact of this interaction
`
`has not been studied. Therefore, extreme caution should be used when these drugs are prescribed in
`
`Reference ID: 3089791
`
`9
`
`
`

`

`combination with Korlym. The benefit of concomitant use of these agents should be carefully weighed
`
`against the potential risks. The dose of Korlym should be limited to 300 mg and used only when
`necessary. [See Warnings & Precautions (5.6)]
`
`
`
`Moderate inhibitors of CYP3A, such as amprenavir, aprepitant, atazanavir, ciprofloxacin,
`darunavir/ritonavir, diltiazem, erythromycin, fluconazole, fosamprenavir, grapefruit juice, imatinib, or
`verapamil, should be used with caution when administered in combination with Korlym.
`
`7.3 CYP3A Inducers
`No medications that induce CYP3A have been studied when co-administered with Korlym. Avoid co­
`administration of Korlym and CYP3A inducers such as rifampin, rifabutin, rifapentin, phenobarbital,
`phenytoin, carbamazepine, and St. John’s wort.
`
`7.4 Drugs Metabolized by CYP2C8/2C9
`Because Korlym is an inhibitor of CYP2C8/2C9, concurrent use of Korlym with a drug whose
`
`metabolism is largely or solely mediated by CYP2C8/2C9 is likely to result in increased plasma
`concentrations of the drug.
`
`
`Korlym significantly increased exposure of fluvastatin, a typical CYP2C8/2C9 substrate, in healthy
`
`subjects. When given concomitantly with Korlym, drugs that are substrates of CYP2C8/2C9 (including
`
`non-steroidal anti-inflammatory drugs, warfarin, and repaglinide) should be used at the smallest
`recommended doses, and patients should be closely monitored for adverse effects. [See Clinical
`Pharmacology (12.3)]
`
`
`7.5 Drugs Metabolized by CYP2B6
`Mifepristone is an inhibitor of CYP2B6 and may cause significant increases in exposure of drugs that are
`metabolized by CYP2B6 such as bupropion and efavirenz. Since no study has been conducted to evaluate
`
`the effect of mifepristone on substrates of CYP2B6, the concomitant use of bupropion and efavirenz
`should be undertaken with caution. [See Clinical Pharmacology (12.3)]
`
`
`7.6 Use of Hormonal Contraceptives
`Mifepristone is a progesterone-receptor antagonist and will interfere with the effectiveness of hormonal
`contraceptives. Therefore, non-hormonal contraceptive methods should be used.
`
`
`8 USE IN SPECIFIC POPULATIONS
`
`8.1 Pregnancy
`Category X
`Korlym is contraindicated in pregnancy. Korlym can cause fetal harm when administered to a pregnant
`woman because the use of Korlym results in pregnancy loss. The inhibition of both endogenous and
`exogenous progesterone by mifepristone at the progesterone receptor results in pregnancy loss. If Korlym
`
`is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be
`
`apprised of the potential hazard to a fetus. [See Contraindications (4.1)]
`
`
`Reference ID: 3089791
`
`10
`
`
`

`

`Human Data
`In a report of thirteen live births after single dose mifepristone exposure, no fetal abnormalities were
`noted.
`
`Animal Data
`Teratology studies in mice, rats and rabbits at doses of 0.25 to 4.0 mg/kg (less than human exposure at the
`maximum clinical dose, based on body surface area) were carried out. Because of the anti-progestational
`
`activity of mifepristone, fetal losses were much higher than in control animals. Skull deformities were
`
`detected in rabbit studies at less than human exposure, although no teratogenic effects of mifepristone
`have been observed to date in rats or mice. These deformities were most likely due to the mechanical
`
`effects of uterine contractions resulting from antagonism of the progesterone receptor.
`
`8.3 Nursing Mothers
`Mifepristone is present in human milk of women taking the drug. Because of the potential for serious
`adverse reactions in nursing infants from Korlym, a decision should be made whether to discontinue
`
`nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
`
`8.4 Pediatric Use
`Safety and effectiveness of Korlym in pediatric patients have not been established.
`
`8.5 Geriatric Use
`Clinical studies with Korlym did not include sufficient numbers of patients aged 65 and over to determine
`whether they respond differently than younger people.
`
`
`
`8.6 Renal Impairment
`The maximum dose should not exceed 600 mg per day in renally impaired patients. [See Clinical
`Pharmacology (12.3)]
`
`
`8.7 Hepatic Impairment
`In patients with mild to moderate hepatic impairment, the maximum dose should not exceed 600 mg per
`day. The pharmacokinetics of mifepristone in patients with severe hepatic impairment has not been
`studied, and Korlym should not be used in these patients. [See Clinical Pharmacology (12.3)]
`
`
`8.8 Females of Reproductive Potential
`Due to its anti-progestational activity, Korlym causes pregnancy loss. Exclude pregnancy before the
`
`initiation of treatment with Korlym or if treatment is interrupted for more than 14 days in females of
`reproductive potential. Recommend contraception for the duration of treatment and for one month after
`stopping treatment using a non-hormonal medically acceptable method of contraception. If the patient has
`had surgical sterilization, no additional contraception is needed.
`
`10 OVERDOSAGE
`There is no experience with overdosage of Korlym.
`
`Reference ID: 3089791
`
`11
`
`
`

`

`11 DESCRIPTION
`Korlym (mifepristone) is a cortisol receptor blocker for oral administration. The chemical name of
`mifepristone is 11β-(4-dimethylaminophenyl)-17β-hydroxy-17α-(1-propynyl)-estra-4, 9-dien-3-one. The
`chemical formula is C29H35NO2; the molecular weight is 429.60; and the structural formula is:
`
`
`
`
`
`
`
`
`
`
`
`
`Mifepristone demonstrates a pH-related solubility profile. The greatest solubility is achieved in acidic
`media (~ 25 mg/mL at pH 1.5) and solubility declines rapidly as the pH is increased. At pH values above
`2.5 the solubility of mifepristone is less than 1 mg/mL.
`
`
`Each Korlym tablet for oral use contains 300 mg of mifepristone. The inactive ingredients of Korlym
`
`tablets are silicified microcrystalline cellulose, sodium starch glycolate, hydroxypropylcellulose, sodium
`
`lauryl sulfate, magnesium stearate, hypromellose, titanium dioxide, triacetin, D&C yellow 10 aluminum
`lake, polysorbate 80, and FD&C yellow 6 aluminum lake.
`
`
`12 CLINICAL PHARMACOLOGY
`
`12.1 Mechanism of Action
`Mifepristone is a selective antagonist of the progesterone receptor at low doses and blocks the
`glucocorticoid receptor (GR-II) at higher doses. Mifepristone has high affinity for the GR-II receptor but
`
`little affinity for the GR-I (MR, mineralocorticoid) receptor. In addition, mifepristone appears to have
`little or no affinity for estrogen, muscarinic, histaminic, or monoamine receptors.
`
`12.2 Pharmacodynamics
`Because mifepristone acts at the receptor level to block the effects of cortisol, its antagonistic actions
`
`affect the hypothalamic-pituitary-adrenal (HPA) axis in such a way as to further increase circulating
`cortisol levels while, at the same time, blocking their effects.
`
`Mifepristone and the three active metabolites have greater affinity for the glucocorticoid receptor (100%,
`61%, 48%, and 45%, respectively) than either dexamethasone (23%) or cortisol (9%).
`
`12.3 Pharmaco

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket